Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de‑intensification strategies.
INTRODUCTION Apalutamide is a potent androgen receptor pathway inhibitor with established efficacy in non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer. Emerging evidence has also raised questions regarding the biological impact of early treatment, depth of response, and the potential...